pregabalin sustained release tablet + pregabalin immediate release capsule
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neuropathic Pain
Conditions
Neuropathic Pain, Diabetes Mellitus, Type 2
Trial Timeline
May 12, 2020 → Dec 20, 2022
NCT ID
NCT05624853About pregabalin sustained release tablet + pregabalin immediate release capsule
pregabalin sustained release tablet + pregabalin immediate release capsule is a approved stage product being developed by Yuhan for Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT05624853. Target conditions include Neuropathic Pain, Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05624853 | Approved | Completed |
Competing Products
20 competing products in Neuropathic Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CHF6467 active | Comac Medical | Phase 1/2 | 33 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| OK-101 0.05% + OK-101 0.1% + Placebo | OKYO Pharma | Phase 2 | 44 |
| YHD1119 + Lyrica | Yuhan | Phase 3 | 77 |
| YHD1119 300mg + YHD1119 300mg | Yuhan | Phase 1 | 33 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-1971a + placebo + pregabalin | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Placebo + Mirogabalin | Daiichi Sankyo | Phase 3 | 77 |
| Qutenza | Astellas Pharma | Pre-clinical | 23 |
| Qutenza exposure | Astellas Pharma | Pre-clinical | 23 |
| Duloxetine + Pregabalin + Placebo | Shionogi | Approved | 85 |
| LY3016859 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4065967 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3848575 + Placebo | Eli Lilly | Phase 2 | 52 |
| ABT-639 + pregabalin + Placebo | AbbVie | Phase 2 | 52 |
| onabotulinum toxin A | AbbVie | Phase 2 | 52 |
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85